23 Results
Sort By:
Published on August 30, 2023
A new artificial intelligence tool predicts esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA), a form of stomach cancer, at least three years prior to a diagnosis. Both cancers are highly fatal, and rates have risen sharply over the past five decades. Researchers from the Lieutenant Colonel Charles S. Kettles…
Published on May 4, 2022
Researchers at the Fred Hutchinson Cancer Research Center reports that DNA changes in Barrett’s esophagus (BE) cells that presage esophageal cancer can be spotted years before cancer develops. The characteristic changes include rearrangements of large chunks of DNA and damage to both copies of a tumor-suppressing gene called TP53. The…
Published on August 13, 2021
Abnormal cells that develop into esophageal cancer start life in the stomach, according to scientists at the University of Cambridge. The researchers found that a particular subtype of esophageal cancer—esophageal adenocarcinoma—is always preceded by Barrett’s esophagus, even if these cells are no longer visible at the time of cancer diagnosis.…
Published on February 24, 2020
Lucid Diagnostics, a subsidiary of PAVmed, has launched the EsoGuard Esophageal DNA Test as a laboratory developed test (LDT), after completing CLIA/CAP certification of the test at Lucid’s commercial diagnostic laboratory partner ResearchDx. EsoGuard is designed to facilitate the diagnosis of Barrett’s Esophagus (BE) and related precursors to highly lethal…
Published on January 23, 2019
A scientist at Johns Hopkins has published a paper (“Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett’s Esophagus: A Prospective Validation Study”) in Clinical Cancer Research that he says could finally result in simple and inexpensive screening for esophageal cancer. “Barrett’s esophagus (BE) is the only known…
Published on May 15, 2018
Lucid Diagnostics, a subsidiary of medical device company PAVmed recently signed a worldwide licensing deal with Case Western Reserve University for its EsoCheck technology, a DNA biomarker test that provides a highly accurate diagnosis for Barrett’s Esophagus, a disease that is often early indicator of esophageal cancer. Under the terms…
Published on August 2, 2023
Just four-and-a-half minutes of vigorous activity during daily tasks could reduce the risk of some cancers by up to 32%, according to a large-scale observational study that used data from wearables. Vigorous Intermittent Lifestyle Physical Activity, or ‘VILPA’, was associated with a substantially lower cancer risk in those who engaged…
Published on June 14, 2023
Obesity has been previously linked to an increased risk of cancer, but most studies have not differentiated the risks between male and female patients. A prospective study of more than 400,000 UK Biobank participants, carried out by researchers at Uppsala University, has now found that both overall fat accumulation and…
Published on May 3, 2023
Research to be presented at Digestive Disease Week 2023 indicates that people who undergo bariatric surgery have less than half the risk for developing an obesity-associated cancer than their peers who do not receive weight loss surgery. “The primary benefit people consider when they think about bariatric surgery is weight…
Published on September 21, 2021
Over the last week, the world of cancer research, diagnostics and therapeutics has been congregating on the European Society of Medical Oncology (ESMO) website to view a wide variety of cutting-edge research presentations at the organization’s annual conference. The biggest congress in Europe with a focus on cancer research, the…
Published on April 19, 2021
The FDA has approved Bristol-Myers Squibb’s monoclonal antibody Opdivo (nivolumab) for first-line treatment of gastric cancer in combination with fluoropyrimidine- and platinum-containing chemotherapy. Cancer cells release proteins that can protect themselves from immune T cells that are seeking to destroy them. Nivolumab is a checkpoint inhibitor drug and acts by…
Published on January 22, 2021
Use of a highly personalized approach to treatment including specific monoclonal antibodies tailored to a patient’s biomarker profile improves outcomes for patients with metastatic gastroesophageal cancers, shows research from the University of Chicago. The phase II trial split patients into eight groups depending on the biomarker profile of their individual…
Published on March 4, 2024
New data from the National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) precision medicine clinical trial has shown in a Phase II study that the trastuzumab-pertuzumab combination therapy, already approved for the treatment of HER2-positive breast cancer, shrunk the tumors of several other cancer types. The findings warrant additional…
Published on February 12, 2024
In oncology, biomarkers play a range of crucial roles in many applications, from early detection and diagnosis to treatment options and efficacy. Nonetheless, biomarkers can be elusive, especially at their often-low levels. Still, scientists around the world search for new tools to take on the biomarker challenges, driven by the…
Published on January 18, 2023
The Nasdaq-listed precision oncology firm Leap Therapeutics has merged with the private company Flame Biosciences to get hold of a pipeline of cancer drugs, including antibodies targeting the emerging biomarker Claudin18.2. The combined company will continue as Leap Therapeutics, trade on the Nasdaq and be led by Leap’s existing management…